| Name | Title | Contact Details |
|---|
The Miromatrix Medical technology has the potential to enable the creation of fully biological replacement organs for the human body. In addition to the Company’s internal efforts focused on the development of its first product – a biological mesh for hernia repair – scientists around the globe are working with the Company’s technology and are taking critical steps toward the creation of human organs including the liver, lung, kidney, pancreas and heart. While our biological mesh development program has been conducted internally, our intent is for current and future products to be developed both at Miromatrix and in partnership with the best among those external groups already working with our technology in order to utilize this pre-existing expertise to develop individual products in the most efficacious, cost-effective and timely way possible.
PHS West Inc is a Hanover, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Curative Medical is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
With a growing demand for behavioral health services and a shortage of providers, access to care is challenging. Telepsychiatry is a solution to bridge this gap in care. innovaTel has nationwide network of psychiatrists, nurse practitioners and licensed clinical social workers that connect to organizations virtually through telemedicine.
Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid equips physicians with critical information designed to enable precision medicine. Elucid is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts (“Virtual Transcriptomics”). This unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs. The Elucid software is available for commercial use in the U.S. and Europe